anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention relates to an azo-benzoic acid type compound. The compound has a structure shown by a formula (1). The invention also provides a preparation method of the compound with the structure shown by the formula (1). The invention also provides an application of the azo-benzoic acid type compound or a pharmaceutically acceptable salt and a medicine complex thereof in serving as an agonist for a G-protein coupled receptor 35. The invention also provides an application of the azo-benzoic acid type compound or the pharmaceutically acceptable salt and the medicine complex thereof in preparation of medicines for preventing and/or treating inflammation, asthma, Parkinson's disease, angiocardiopathy and intestinal cancer. The azo-benzoic acid type compound provided by the invention has a relatively high targeting property for the G-protein coupled receptor 35.
A minimum of 46 elderly, students of a informatics course, will participate in the study. Initially, the students will have 8 usual informatics classes in the institution where they were enrolled spontaneously. Then, during the next 8 classes (from class 9 to class 16) they will practice 10 minutes of virtual reality games, as part of the class.
This investigator-initiated randomized trial is being conducted to test whether abatacept, as compared to placebo, is associated with a reduction in MACE among participants who develop myocarditis after treatment with an ICI. Immune checkpoint inhibitors leverage the immune system to treat a wide variety of cancers. Myocarditis is an uncommon immune related adverse event (irAE) secondary to treatment with an ICI. The guideline recommended treatment for ICI myocarditis is cessation of the ICI and administration of corticosteroids. However, despite administration of corticosteroids, the rate of MACE with ICI myocarditis is high. Data from multiple independent international cohorts have shown that the rate of MACE with ICI myocarditis despite administration of corticosteroids ranges from 25-50%.For comparison, the rate of MACE with myocarditis unrelated to an ICI is \<5%.

Abatacept is a selective co-stimulation modulator that inhibits T cell (T lymphocyte) activation by binding to CD80 and CD86, thereby blocking its interaction with CD28. This interaction provides a costimulatory signal necessary for full activation of T lymphocytes. In animal studies of ICI myocarditis, the administration of abatacept led to a reduction in cardiac immune activation and an increase in survival. In retrospective unpublished clinical data, the administration of abatacept to participants with ICI myocarditis on corticosteroids was associated with a reduction in risk of MACE. There are no prospective studies testing whether abatacept is effective among participants with ICI myocarditis. Therefore, the primary aim of this trial is to test in a randomized double-blind placebo-controlled study whether abatacept, administered concurrently with corticosteroids, is associated with a reduction in MACE among participants with recently diagnosed ICI myocarditis
RECOMBINATE [Antihemophilic Factor (Recombinant)] is a glycoprotein synthesized by a genetically engineered Chinese Hamster Ovary (CHO) cell line. In culture, the CHO cell line secretes recombinant Factor VIII (rFVIII) into the cell culture medium. The rFVIII is purified from the culture medium utilizing a series of chromatography columns. A key step in the purification process is an immunoaffinity chromatography methodology in which a purification matrix, prepared by immobilization of a monoclonal antibody directed to Factor VIII, is utilized to selectively isolate the rFVIII in the medium. The synthesized rFVIII produced by the CHO cells has the same biological effects as human Factor VIII. Structurally the protein has a similar combination of heterogenous heavy and light chains as found in human Factor VIII.

RECOMBINATE is formulated as a sterile, nonpyrogenic, off-white to faint yellow, lyophilized powder preparation of concentrated recombinant Factor VIII for intravenous injection. RECOMBINATE is available in single-dose vials, which contain nominally 250, 500 and 1000 International Units per vial. When reconstituted with the appropriate volume of diluent, the product contains the following stabilizers in maximum amounts: For 5 mL reconstitution volume: 25 mg/mL Albumin (Human), 0.40 mg/mL calcium, 3 mg/mL polyethylene glycol (3350), 360 mEq/L sodium, 110 mM histidine, 1.5 µg/Factor VIII International Unit (IU) polysorbate-80. Recombinant Von Willebrand Factor (rVWF) is coexpressed with the rFVIII and helps to stabilize it. The final product contains not more than 2 ng rVWF/IU rFVIII, which will not have any clinically relevant effect in patients with von Willebrand’s disease. The product contains no preservative.

Manufacturing of RECOMBINATE is shared by Baxter Healthcare Corporation and Wyeth BioPharma. The recombinant Antihemophilic Factor Concentrate (For Further Manufacturing Use), is produced by Baxter Healthcare Corporation and Wyeth BioPharma (For Further Manufacturing Use) and subsequently formulated and packaged at Baxter Healthcare Corporation.

Each vial of RECOMBINATE is labeled with the Factor VIII activity expressed in IU per vial. Biological potency is determined by an in vitro assay which is referenced to the World Health Organization (WHO) International Standard for Factor VIII:C Concentrate.
A method and a system for remotely verifying a prescription are described herein. In particular, a first site may provide prescription information based on a prescription of a patient to a second site. The prescription information is inputted by a staff member at the first site. The second site is remotely located from the first site and operatively coupled to the first site. The first site may also provide a prescription image based on the prescription so that a pharmacist at the second site may review and compare the prescription information and the prescription image. Further, the first site may provide medical information associated with the patient to the second site so that the pharmacist at the second site may review and determine a condition suggesting a potential for an adverse effect on the patient by the drugs based on the medical information.
The most common adverse reactions occur at the application site, including dermatitis, itching or scaling. These tend to be dose-‑‐limiting and diminish with time.

Serious adverse experiences following the administration of Lidothol are similar in nature to those observed in other amide anesthetic-‑‐containing agents. These adverse experiences are, in general, dose-‑‐related and may result from high plasma levels caused by excessive dosage, rapid absorption, or may result from hypersensitivity, idiosyncrasy, or a diminished tolerance on the part of the patient. Serious adverse experiences are generally systemic in nature. During or immediately after treatment with Lidothol, the skin at the site of application may develop redness, blisters, bruising, burning sensation, depigmentation, dermatitis, or mild irritation.

Allergic Reactions

Allergic and anaphylactoid reactions associated with Lidocaine, although rare, can occur. They are characterized by angioedema, bronchospasm, dermatitis, dyspnea, hypersensitivity, laryngospasm, pruritus, shock, and urticaria. If they occur, consult your doctor.
PROBLEM TO BE SOLVED: To easily extract information on a visiting customer from a data base without allowing him to be aware thereof by setting at least one of leans diopters or frame product number of spectacles as a retrieval condition so as to extract customer data filed in the data base. SOLUTION: To remake spectacles, correction diopters need to be formulated in consideration of the currently used lens diopters. For this purpose, the spectacles that a visiting customer wears or carries are received and a lens meter measures the lens diopters, namely, S(sphericity), C(astigmatism), and A(axis angle of astigmatism). When the lens diopters are obtained, a retrieval screen 30 is displayed on a display and input is done based on a retrieval item 31 for 'spectacle diopters'. Further, the number of the spectacle frame is given thereto, so the product number of the spectacle frame is confirmed and input is done based on a retrieval item 32 for 'frame product number'. Then retrieval is carried on by clicking a retrieval start key 33 with a mouse.
BACKGROUND: Primary dysfunction and rejection are more common in donor liver tissues with steatosis. AMP-activated protein kinase (AMPK) assumes organ-protective functions during ischemia. Metformin was used for the activation of AMPK in hepatocytes. The aim of this study is to investigate the effectiveness of metformin administration for the reversal of cold-ischemia-induced damage in hepatosteatosis.
MATERIAL AND METHODS: Seven-week-old C7BL56 male-mice (n = 109) were separated into four groups depending on diet type and metformin use. A specific diet model was followed for 10 weeks to induce hepatosteatosis. A group of the animals was administered with metformin for the last four weeks via oral gavage. After resection, the liver tissues were perfused and kept for 0-6-12-24 h in the UW solution. Histopathological examinations were performed, and Western blot was utilized to analyze p-AMPK and AMPK expression levels.
RESULTS: Hepatosteatosis decreased significantly with metformin. The steatotic liver group had more prominent pericentral inflammation, necrosis as well as showing a decreased and more delayed AMPK response than the non-fat group. All these alterations could be corrected using metformin.
CONCLUSION: Metformin can increase the resistance of livers with hepatosteatosis to cold-ischemia-induced damage, which in turn may pave the way for successful transplantation of fatty living-donor livers.
This study aims to answer the question: What is the impact of an income security health promotion service based in a primary care setting on the income security of people living in poverty? We hypothesize that an income security health promotion service for adults living in poverty will increase monthly income relative to usual care. We will carry out a pragmatic randomized controlled trial that evaluates the impact of such a new service focused on income security health promotion. The St. Michael's Hospital Academic Family Health Team has received ongoing funding from the Ministry of Health and Long-Term Care (MOHLTC) to support this service. The primary outcome is income security, and secondary outcomes include quality of life, financial literacy and community integration.

Population - Adults living in poverty Intervention - Income security health promotion Control - Usual care Outcome - Primary: Improvement in income per month in the intervention group at 6 months (post-intervention) compared to income in control group at 6 months (pre-intervention). Secondary: quality of life, self-rated health, community engagement.
The present disclosure relates to a system and method for automatically detecting Rapid Eye Movement (REM) sleep and delivering sensory stimulation to extend REM duration without disturbing sleep. The sensory stimulus may be an auditory or other stimulus. The system and method ensure timely delivery of stimulation and automatically adjust the amount, intensity, and/or timing of stimulation as needed. REM sleep is detected based on brain activity, heart activity, and/or other information. REM sleep may be detected and/or predicted by a trained neural network. The amount, timing, and/or intensity of sensory stimulation may be determined and/or adjusted based on one or more values of one or more intermediate layers of the neural network and one or more brain activity and/or cardiac activity parameters to enhance REM sleep in the subject.
Placebo injected subcutaneously twice daily for up to 52 weeks. De novo (New) participants, who did not participate in the previous relamorelin studies, began the study with a 2-week placebo run-in.
PURPOSE: Management of cervical radicular pain is complex and may be resistant to conservative treatment. The primary aim of this study was to evaluate the efficacy of ultrasound-guided selective cervical nerve root pulsed radiofrequency (US-SCNR PRF) treatment in patients with radicular neck pain due to cervical disc herniation who did not respond to conservative treatment. The secondary aim was to determine the efficacy of the treatment in terms of functionality, neuropathic pain, and treatment-related adverse events.
METHODS: This study included 62 patients with chronic cervical radicular pain who underwent US-SCNR PRF treatment. Pain intensity was assessed using the Numerical Rating Scale before treatment and at 1, 3, and 6 months after treatment. The Neck Disability Index and Douleur Neuropathique 4 Questions were used to assess functionality and neuropathic pain before and 6 months after treatment. Significant pain relief was defined as ≥ 50% reduction in the pain score compared with the pre-treatment score.
RESULTS: Cervical radicular pain was significantly reduced at 1, 3, and 6 months after pulsed radiofrequency compared to pre-treatment (P < 0.001). Successful pain relief was achieved in 59.6% of the patients at 6 month. However, there was no significant difference between the mean pain scores in the 1st month, 3rd month and 6th month. In addition, the functionality and neuropathic pain scores were significantly reduced at 6 month.
CONCLUSIONS: These results suggest that US-SCNR PRF treatment is effective for cervical radicular pain, functionality, and neuropathic pain for at least six months in the majority of patients with refractory cervical radicular pain, and is considered a safer and preferable treatment modality due to real-time visualization of the cervical nerve roots and adjacent neurovascular structures and no radiation exposure.
Obstructive sleep apnea, a common form of sleep-disordered breathing, is characterized by intermittent cessations of breathing that reduce blood oxygen levels and contribute to the development of hypertension. Hypertension is a major complication of obstructive sleep apnea that elevates the risk of end-organ damage. Premenopausal women have a lower prevalence of obstructive sleep apnea and cardiovascular disease than men and postmenopausal women, suggesting that sex hormones play a role in the pathophysiology of sleep apnea-related hypertension. The lack of protection in men and postmenopausal women implicates estrogen and progesterone as protective agents but testosterone as a permissive agent in sleep apnea-induced hypertension. A better understanding of how sex hormones contribute to the pathophysiology of sleep apnea-induced hypertension is important for future research and possible hormone-based interventions. The effect of sex on the pathophysiology of sleep apnea and associated intermittent hypoxia-induced hypertension is of important consideration in the screening, diagnosis, and treatment of the disease and its cardiovascular complications. This review summarizes our current understanding of the impact of sex hormones on blood pressure regulation in sleep apnea with a focus on sex differences.
<P>PROBLEM TO BE SOLVED: To provide a structured composition decreasing liability of slipping all over the wet skin or on a floor of a shower room before a personal care product such as a body soap once squeezed out from a container and rubbed against the whole skin, and to provide a method for applying the composition on the body.  <P>SOLUTION: Provided is a method of applying a structured composition 10 to a body, which method comprises making a substrate into contact with a structured composition such that a plurality of channels 12 are disposed between the composition and the substrate. The plurality of channels preferably comprise channels having a height of from about 0.5 mm to about 5 mm. The plurality of channels preferably comprises at least two channels that differ in size, shape, or both. The plurality of channels preferably comprises from 2 to 20 channels. The composition preferably comprises one or more surfactants and at least one structuring agent.  <P>COPYRIGHT: (C)2010,JPO&INPIT
CONTEXT: Chronic hyperglycemia in patients with diabetes mellitus (DM) causes retinal damage and leakage, resulting in vision loss. Although diabetic retinopathy (DR) and diabetic kidney disease (DKD) are usually correlated, the relationship between diabetic macular edema (DME) and DKD remains unknown.
OBJECTIVE: To assess whether DME presence can predict renal failure in patients with DM and chronic kidney disease (CKD).
METHODS: This retrospective cohort study used data from 120 healthcare organizations in the TriNetX network. Electronic medical records of approximately 90 million patients were reviewed. The study population was classified into DME and non-DME cohorts. Primary and secondary outcomes were new-onset end-stage renal disease (ESRD) and all-cause mortality, respectively. Covariate factors were incorporated to reduce confounding effects.
RESULTS: Before matching, the DME cohort used more medication and had poorer renal function and blood sugar control than the non-DME cohort. Subsequently, the 2 groups were well-matched in demographics, socioeconomic status, lifestyle, comorbidities, and medication usage. The DME cohort had a significantly higher risk of ESRD, dialysis, and renal transplantation than the non-DME cohort. Subgroup analyses showed consistent results irrespective of follow-up duration, initial estimated glomerular filtration rate, or glycated hemoglobin levels. Additionally, the DME cohort had a lower risk of all-cause mortality than the non-DME cohort.
CONCLUSION: Statistically significant 5-year increased risks of ESRD, dialysis, and renal transplantation were observed in patients with concurrent DME. Therefore, close monitoring and follow-up of the renal function in DM patients with DME are necessary and strongly recommended.
PURPOSE: To investigate the histopathological changes following subretinal amniotic membrane transplantation in an in vivo porcine model of retinal holes.
METHODS: Left eyes of 12 Danish Landrace pigs were vitrectomized under full anesthesia. A subretinal bleb was created before excising a retinal hole (1154-2934 µm) using a 23-gauge vitrector. The pigs underwent transplantation of human freeze-dried amniotic membrane into the subretinal space, with no tamponade applied. Optical coherence tomography and color fundus photography were performed just after surgery and at 2 and 4 weeks post-surgery. At the end of follow-up, the eyes were enucleated for hematoxylin and eosin staining and fluorescence immunohistochemistry, using antibodies against retinal glial cells and inner retinal neurons.
RESULTS: The amniotic membrane sheets facilitated hole closure by gliosis and centripetal migration of the edges of the hole. Immunohistochemical examination showed that the cells within the closed hole expressed anti-glial fibrillary acidic protein (GFAP) and anti-S100B, but not anti-glutamine synthetase (GS), suggesting that astrocytes were the predominant glial cells involved in hole closure. Gliosis was observed between the amniotic membrane sheet and the overlying photoreceptors of the surrounding retina. Morphological restoration of the retinal layers within the closed retinal hole was not observed.
CONCLUSIONS: The amniotic membrane acted as a stimulator for retinal hole closure by inducing glial cell proliferation and providing a scaffold for the centripetal migration of the edges of the hole. No morphological restoration was observed.
A composition to relieve itch, pain and swelling associated with a bite or sting, comprising a proteolytic enzyme dissolved in water, an anti-bacterial agent, and a pH lowering agent. The composition is in a dispensing container, and is devoid of other ingredients that may mask the effectiveness of the enzyme. In one form a liquid propellant floats on the composition and a dip tube extends from a discharge valve into the composition. In another form, a piston separates the composition from a pressurized gaseous propellant. In another form, the composition is in a bag in the container and pressurized gaseous propellant surrounds the bag. In a further form the bag is an elastic material that exerts pressure on the composition. In other forms the container is a single use bladder or pouch. The proteolytic enzyme preferably is a meat tenderizer such as Papain or Bromelain.
Adolescents with single ventricle heart disease (SVHD) show brain injuries in sites (hippocampus, mammillary bodies, thalamus, and frontal cortices) that are associated with cognitive deficits, in particular working memory. A key component of cognition, and thus, an important influence on academic performance, self-care ability, quality of life, and morbidity and mortality, is working memory. However, it is unclear whether cognition, as well as brain tissue integrity can be improved with cognition intervention. Among available interventions, a possible intervention to improve working memory and brain status in SVHD is Cogmed®, which is an interactive, computer-based intervention, specifically designed for children and young adults, to improve attention and working memory with significant effectiveness in other pediatric conditions associated with brain injury. A unique feature of the Cogmed ® program is the in-home support of trained coaches for the duration of the intervention (5 days/week for 5 weeks), which optimizes adherence and confirms completion of the tasks. The investigators will use a one group pre- post-intervention design, 20 subjects (10 males and 10 females), with inclusion criteria: 14-18 years of age, have undergone surgical palliation, and score 25-10 (mild to moderate cognitive impairment) on the Montreal Cognitive Assessment (MoCA) screener. Using non-invasive brain magnetic resonance imaging (MRI) procedures, diffusion tensor imaging (DTI) based mean diffusivity (MD), an MRI measure of tissue integrity, can identify changes in the hippocampus, mammillary bodies, thalamus, and frontal cortices pre- and post- cognitive intervention. Therefore, the specific aims of this proposal are to: 1) examine the impact of Cogmed® intervention on working memory (working memory index \[WMI\] score from the WRAML2) in adolescents with SVHD (pre- and post-intervention); 2) assess the effect of Cogmed® on brain structural integrity (DTI-based MD procedures) in sites that control memory (hippocampus, mammillary bodies, thalamus, and frontal cortices) in adolescents with SVHD (pre- and post-intervention); and 3) examine if there is an impact of the Cogmed® intervention on cognition and brain tissue integrity based on sex in SVHD.

In summary, SVHD adolescents have significant cognitive deficits that are linked to brain injury in regions, which control such functions. Intervention to improve cognition and brain injury in SVHD is unclear, but a potential innovative treatment for such symptoms and brain injury is Cogmed®. The information from this pilot study has the potential to revolutionize the clinical treatment specific to cognitive deficits in SVHD and other types of congenital heart defects. In addition, the clinical implications are considerable as improved working memory skill has the potential to increase academic achievement, improve self-care, reduce mortality and morbidity, and increase quality of life in this high risk, growing population.